The short bowel syndrome therapy developer has added $110m to the $35m with which it emerged from stealth in January.

TD Ameritrade and QBE-backed automation software producer Hyperscience has now raised in excess of $190m in total, Tiger Global Management leading its latest round.

Taiho Ventures and SR One co-led a series A round that will fund the early clinical progress of Dren's cancer and protein-depletion drug candidates.

The round was led by $8m from Leaps by Bayer and increased the microbiome skin treatment developer's total funding to $34m.

Nelson Education participated in a $15.2m round for Knowledgehook, which is mulling the expansion of its maths learning assessement platform to other subjects.

Eli Lilly will acquire the WUSTL-linked neurological disease therapy developer in a $135m deal that could top $1.2bn with milestone payments.

Roche and Novo-backed small molecule therapy developer Aligos Therapeutics has floated in an initial public offering priced in the middle of its range.

Nan Fung-backed hearing aid producer Eargo's shares opened at double its IPO price after it floated above its range.

Eli Lilly will acquire the AbbVie-backed neurological disease therapy developer in a $135m transaction that could top $1.2bn with milestone payments.

AMS, a developer of energy value assessment software, had raised $52m from investors including Engie, AGL Energy, Southern Company and GE Ventures.